Dr Christina Reith
BSc (Hons), MBChB (Hons), FRCP (Glasg.), FFPM
Senior Clinical Research Fellow
- Honorary Consultant Physician, Pharmaceutical Medicine, Oxford University Hospitals NHS Foundation Trust
Christina studied at The University of Glasgow, gaining a first class honours degree in medical biochemistry and subsequently her medical degree, when she was jointly awarded the Brunton Medal for the most distinguished graduate in medicine.
Christina completed her MRCP whilst working in the NHS, and subsequently completed speciality training in Pharmaceutical Medicine in 2011. She became a Fellow of The Royal College of Physicians and Surgeons of Glasgow in 2012, and a Fellow of the Faculty of Pharmaceutical Medicine in 2013.
Christina mainly works on large-scale clinical trials and meta-analyses in relation to cardiovascular disease, with a particular research interest being the reliable assessment of drug safety using such large-scale randomized data. She has worked closely on the Study of Heart and Renal Protection (SHARP), the largest ever trial in patients with moderate-to-severe chronic kidney disease (CKD), recruiting 9438 patients in nearly 400 hospitals in 18 countries, and is currently focused on meta-analyses such as those conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration and Antithrombotic Trialists’ (ATT) Collaboration. She has an interest in streamlining clinical trial methodology, and is a member of the international Clinical Trials Transformation Initiative (CTTI) which considers how best to conduct trials efficiently.
Christina is also involved in teaching (eg, on the NDPH Global Health Sciences MSc), is a GMC-approved Educational Supervisor for Pharmaceutical Medicine specialty training, and acts as a College Adviser for students at Green Templeton College.
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612
A pragmatic tool for drug discovery.
Bobbitt DR. et al, (2020), Drug Discov Today
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.
Preiss D. et al, (2020), J Am Coll Cardiol, 75, 1945 - 1955
CV Care: Lipid-modifying Agents--From Statins to PCSK9 inhibitors
PREISS D. and REITH C., (2019), JACC - Journal of the American College of Cardiology
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I. et al, (2019), Kidney Int, 96, 170 - 179